Related Experiment Video

Updated: Jun 14, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Upfront use of gemtuzumab ozogamicin in young children with CD33-positive AML

Dror Sayar1, Yoav Burstein, Bela Bielorai

  • 1Pediatric Hemato-Oncology Unit, Dana Children's Hospital (affiliated to the Sackler Faculty of Medicine), Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. drorsayar@gmail.com

Pediatric Blood & Cancer
|March 24, 2010
PubMed

Insights

Gemtuzumab ozogamicin (GO) showed good tolerability and efficacy in young children with acute myeloid leukemia (AML). This antibody treatment helped achieve remission, though transplant complications and relapse impacted survival outcomes.

Area of Science:

  • Hematology
  • Pediatric Oncology
  • Immunotherapy

Background:

  • Gemtuzumab ozogamicin (GO) is an anti-CD33 antibody therapy for CD33-positive acute myeloid leukemia (AML).
  • Limited data exists on GO's safety and efficacy in very young pediatric patients.

Observation:

  • Three young children (two infants, one toddler) with AML received GO at 9 mg/m(2).
  • Two patients received GO at diagnosis with chemotherapy; one received it post-relapse.
  • All patients underwent hematopoietic stem cell transplantation.

Findings:

  • Gemtuzumab ozogamicin was well tolerated in this cohort.
  • All three children achieved remission after GO treatment.
  • Survival varied: one relapsed and died, one died from transplant-related pulmonary fibrosis, and one survived long-term.

Implications:

  • GO demonstrates potential as a well-tolerated and effective treatment option for pediatric AML.
  • Further research is needed to optimize GO use and manage potential toxicities in young children.
  • Understanding long-term outcomes and transplant interactions is crucial for improving survival in this population.

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...